Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting
Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
MarketBeat on MSN9d
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences Inc. (NASDAQ: SAVA) is a biotech developing treatments for Alzheimer's disease. The company has a lot of ...
Looking At Cassava Sciences's Recent Unusual Options Activity
Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...
Cassava Sciences: Pivotal Alzheimer's Data May Push Stock Toward Book Value
Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...
pharmaphorum2d
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal casts long shadow
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Cassava Sciences put volume heavy and directionally bearish
Bearish flow noted in Cassava Sciences (SAVA) with 2,978 puts trading, or 1.3x expected. Most active are Nov-24 27 puts and Dec-24 10 puts, ...
ETF Daily News1mon
Cassava Sciences (NASDAQ:SAVA) Shares Gap Up – What’s Next?
Cassava Sciences, Inc. (NASDAQ:SAVA – Get Free Report)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $25.41, but opened at $27.24.
Morningstar8d
Cassava Sciences Inc SAVA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
Cassava Sciences has faced a lot of scrutiny, with key figures resigning and the company settling an SEC penalty. Read what ...